Danaher (NYSE:DHR) Updates FY 2026 Earnings Guidance

Danaher (NYSE:DHR) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 8.350-8.550 for the period, compared to the consensus earnings per share estimate of 8.400. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Wolfe Research dropped their price objective on Danaher from $260.00 to $230.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Rothschild & Co Redburn set a $205.00 price objective on Danaher in a report on Friday. The Goldman Sachs Group dropped their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Monday, April 13th. JPMorgan Chase & Co. increased their price objective on Danaher from $270.00 to $275.00 and gave the company an “overweight” rating in a report on Thursday, January 29th. Finally, Guggenheim increased their price objective on Danaher from $250.00 to $275.00 and gave the company a “buy” rating in a report on Friday, January 2nd. Eighteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $246.75.

Danaher Stock Down 0.4%

Shares of NYSE DHR opened at $194.75 on Wednesday. The stock has a market cap of $137.83 billion, a PE ratio of 38.64, a price-to-earnings-growth ratio of 2.66 and a beta of 0.95. The company has a quick ratio of 1.51, a current ratio of 1.87 and a debt-to-equity ratio of 0.35. Danaher has a 52-week low of $180.03 and a 52-week high of $242.80. The business has a 50-day moving average price of $197.89 and a 200 day moving average price of $214.56.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. The firm had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The business’s revenue was up 3.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.88 EPS. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. Equities research analysts forecast that Danaher will post 8.4 earnings per share for the current year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Friday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.32. Danaher’s payout ratio is 31.75%.

Insiders Place Their Bets

In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total transaction of $274,573.20. Following the completion of the sale, the executive vice president directly owned 5,099 shares of the company’s stock, valued at approximately $1,060,642.99. This trade represents a 20.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.80% of the company’s stock.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Earnings beat and EPS strength — Danaher reported Q1 non‑GAAP EPS of $2.06 versus consensus ~ $1.94, showing margin resilience and beating estimates which supported an initial positive market reaction. Danaher (DHR) Q1 Earnings Beat Estimates
• Positive Sentiment: Guidance raised — Management lifted the top end of FY2026 EPS guidance to a range of 8.350–8.550, signaling confidence in ongoing biotech/life sciences demand and supporting upside to longer‑term earnings expectations. Danaher rises after lifting full-year earnings outlook
• Positive Sentiment: Bioprocessing and Life Sciences momentum — Strong demand for bioprocessing tools and double‑digit growth in Biotechnology & Life Sciences were cited repeatedly on the call and in coverage, a high‑margin growth driver that investors favor. Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains
• Neutral Sentiment: Conference call and materials available — Detailed slide deck and earnings‑call transcript provide management’s color on segment trends and the Masimo-related positioning; useful for investors doing deeper due diligence. Press Release / Slide Deck
• Neutral Sentiment: Analyst/coverage pieces weigh pros/cons — Several outlets compared Danaher to peers and highlighted valuation metrics (PE, PEG) versus longer‑term growth expectations; could influence flow but not an immediate catalyst. Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
• Negative Sentiment: Revenue miss — Reported revenue of $5.95B fell short of consensus (~$6.0B). A top‑line miss reduced investor enthusiasm despite the EPS beat, pressuring the stock after the initial rally. Danaher (NYSE:DHR) Misses Q1 CY2026 Revenue Estimates
• Negative Sentiment: Diagnostics and respiratory softness — Management flagged weaker Diagnostics results and lowered the respiratory outlook, which creates near‑term downside risk in lower‑growth segments and drove negative headlines. Danaher Q1 Earnings Beat Estimates, But Revenue Miss, Weak Diagnostics Weigh On Stock

Institutional Trading of Danaher

A number of hedge funds have recently added to or reduced their stakes in the stock. Compound Planning Inc. lifted its position in Danaher by 47.1% during the 4th quarter. Compound Planning Inc. now owns 9,554 shares of the conglomerate’s stock worth $2,187,000 after acquiring an additional 3,060 shares during the period. Invesco Ltd. lifted its holdings in shares of Danaher by 8.1% in the 4th quarter. Invesco Ltd. now owns 4,120,223 shares of the conglomerate’s stock valued at $943,201,000 after buying an additional 307,095 shares during the period. Birchwood Financial Partners Inc. acquired a new stake in shares of Danaher in the 4th quarter valued at approximately $41,000. Corient Private Wealth LLC lifted its holdings in shares of Danaher by 2.0% in the 4th quarter. Corient Private Wealth LLC now owns 1,025,570 shares of the conglomerate’s stock valued at $228,812,000 after buying an additional 19,852 shares during the period. Finally, Alpine Woods Capital Investors LLC acquired a new stake in shares of Danaher in the 4th quarter valued at approximately $231,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.